Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants

被引:0
|
作者
Alessandra Zanetti [1 ]
Francesca D’Avanzo [2 ]
Rosella Tomanin [1 ]
机构
[1] Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children’s Health, University of Padova, Padova
[2] Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova
关键词
Enzyme replacement therapy; Hunter syndrome; IDS; IDS variants; IDSP1; Iduronate; 2-sulfatase; Lysosomal storage disorder; MPS II; Mucopolysaccharidosis type II; Recombination; Variants classification;
D O I
10.1186/s40246-024-00701-w
中图分类号
学科分类号
摘要
Purpose: Mucopolysaccharidosis type II (MPS II) is a rare X-linked lysosomal storage disorder caused by genetic alterations in the iduronate 2-sulfatase (IDS) gene. A wide range of variants has been reported for different countries and ethnic groups. We collected, analyzed and uniformly summarized all published IDS gene variants reported in literature up to June 2023, here providing the first worldwide review and classification. Methods: Data was obtained from a literature search, conducted in PubMed and Google. All data was analyzed to define the most common alleles, geographic distribution and genotype-phenotype correlation. Moreover, point variants were classified according to their pathogenicity, based on the ACMG guidelines. Results: Several types of variants have been described in the IDS gene, including intrachromosomal homologous recombination occurring between the homologous regions of IDS gene and its pseudogene IDSP1. Overall, we collected 2852 individuals from 2798 families, including 24 female patients. Most families carried missense variants, followed by large deletions-insertions and complex rearrangements, small frameshift deletions/insertions and nonsense variants. Based on ACMG guidelines, 62.9% of the 779 point variants were classified as “pathogenic”, 35.4% as “likely pathogenic”, and the remaining 13 variants as having “uncertain significance”. Conclusion: Data from this study confirmed that MPS II is a genetically very heterogeneous disorder, making genotype-phenotype correlation very challenging and in most cases merely unfeasible. Mutation updates are essential for the correct molecular diagnosis, genetic counseling, prenatal and preimplantation diagnosis, and disease management. © The Author(s) 2024.
引用
收藏
相关论文
共 50 条
  • [21] Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line
    Altarescu, Gheona
    Renbaum, Paul
    Eldar-Geva, Talia
    Brooks, Baruch
    Varshaver, Irit
    Avitzour, Mical
    Margalioth, Ehud J.
    Levy-Lahad, Ephrat
    Elstein, Deborah
    Epsztejn-Litman, Silvina
    Eiges, Rachel
    PRENATAL DIAGNOSIS, 2011, 31 (09) : 853 - 860
  • [22] Successful Desensitization to Idursulfase in a Patient with Type II Mucopolysaccharidosis (Hunter syndrome)
    Serrano, C. D.
    Gomez, J. F.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (07) : 571 - 572
  • [23] Prenatal diagnosis and genetic counseling of mucopolysaccharidosis type II (Hunter syndrome)
    Chen, C-P
    Lin, S. P.
    Tzen, C.-Y.
    Hwu, W. L.
    Chern, S. R.
    Chuang, C. K.
    Chiang, S. S.
    Wang, W.
    GENETIC COUNSELING, 2007, 18 (01): : 49 - 56
  • [24] Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
    Yamanishi, Ryutaro
    Nakamura, Natsuko
    Tsunoda, Kazushige
    CASE REPORTS IN OPHTHALMOLOGY, 2019, 10 (02): : 186 - 194
  • [25] Cervical decompression in mild mucopolysaccharidosis type II (Hunter syndrome)
    OBrien, DP
    Cowie, RA
    Wraith, JE
    CHILDS NERVOUS SYSTEM, 1997, 13 (02) : 87 - 90
  • [26] Cervical decompression in mild mucopolysaccharidosis type II (Hunter syndrome)
    D. P. O'Brien
    R. A. Cowie
    J. E. Wraith
    Child's Nervous System, 1997, 13 : 87 - 90
  • [27] Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl
    Semyachkina, A. N.
    Voskoboeva, E. Y.
    Zakharova, E. Y.
    Nikolaeva, E. A.
    Kanivets, I. V.
    Kolotii, A. D.
    Baydakova, G. V.
    Kharabadze, M. N.
    Kuramagomedova, R. G.
    Melnikova, N. V.
    BMC MEDICAL GENETICS, 2019, 20
  • [28] Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): A case report
    Shah G.S.
    Mahal T.
    Sharma S.
    Journal of Medical Case Reports, 4 (1)
  • [29] Identification and structure characterization of novel IDS variants causing mucopolysaccharidosis type II: A retrospective analysis of 30 Chinese children
    Zhao, Xiao-Ying
    Qiao, Guang-Ming
    Liu, Fang
    CLINICA CHIMICA ACTA, 2021, 523 : 386 - 394
  • [30] Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome)
    Tomanin, R
    Friso, A
    Alba, S
    Puicher, EP
    Mennuni, C
    La Monica, N
    Hortelano, G
    Zacchello, F
    Scarpa, M
    ACTA PAEDIATRICA, 2002, 91 : 100 - 104